Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?

Authors

  • Carlos Eduardo Paiva
  • Bianca Sakamoto Ribeiro Paiva
  • Odair Carlito Michelin

Downloads

Download data is not yet available.

Author Biographies

Carlos Eduardo Paiva

MD, MSc. PhD student and clinical oncologist, Oncological and Hemato-Oncological Center, Universidade Estadual Paulista (Unesp), Botucatu, São Paulo, Brazil.

Bianca Sakamoto Ribeiro Paiva

RN, MSc. PhD student and assistant nursing professor, Department of Nursing, Botucatu Medical School, Universidade Estadual Paulista (Unesp), Botucatu, São Paulo, Brazil.

Odair Carlito Michelin

MD, PhD. Associate professor, Department of Clinics, Botucatu Medical School, Universidade Estadual Paulista (Unesp), Botucatu, São Paulo, Brazil.

References

Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the preven- tion of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278-85.

Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after mode- rately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-30.

van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008;11(3):77-98.

de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepi- tant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56(4):370-8.

Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexametha- sone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients recei- ving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529-35.

Downloads

Published

2009-11-11

How to Cite

1.
Paiva CE, Paiva BSR, Michelin OC. Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?. Sao Paulo Med J [Internet]. 2009 Nov. 11 [cited 2025 Mar. 9];127(6):385-6. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/1927

Issue

Vol. 127 No. 6 (2009)

Section

Letter to the Editor

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.